WO2008114812A1 - Jak inhibitor - Google Patents

Jak inhibitor Download PDF

Info

Publication number
WO2008114812A1
WO2008114812A1 PCT/JP2008/055052 JP2008055052W WO2008114812A1 WO 2008114812 A1 WO2008114812 A1 WO 2008114812A1 JP 2008055052 W JP2008055052 W JP 2008055052W WO 2008114812 A1 WO2008114812 A1 WO 2008114812A1
Authority
WO
WIPO (PCT)
Prior art keywords
jak
substituted
disclosed
jak inhibitor
acceptable salt
Prior art date
Application number
PCT/JP2008/055052
Other languages
French (fr)
Japanese (ja)
Inventor
Yukimasa Shiotsu
Kenichi Ishii
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Publication of WO2008114812A1 publication Critical patent/WO2008114812A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a JAK inhibitor containing an indazole derivative represented by the formula (I) below (wherein R1 represents a substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group) or a pharmacologically acceptable salt thereof as an active ingredient. Also disclosed is an agent for treatment of diseases associated with JAK. Further disclosed is a JAK inhibitor containing an indazole derivative represented by the formula (Ia) below [wherein R2 represents CONR4aR4b (wherein R4a and R4b may be the same or different and represent a hydrogen atom, a substitutedor unsubstituted lower alkyl or the like, or alternatively R4a and R4b may form a substituted or unsubstituted heterocyclic group together with an adjacent nitrogen atom) or the like, and R3 represents a hydrogen atom or the like] or a pharmacologically acceptable salt thereof as an active ingredient. Still further disclosed is an agent for treatment of diseases associated with JAK.
PCT/JP2008/055052 2007-03-19 2008-03-19 Jak inhibitor WO2008114812A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007069776 2007-03-19
JP2007-069776 2007-03-19

Publications (1)

Publication Number Publication Date
WO2008114812A1 true WO2008114812A1 (en) 2008-09-25

Family

ID=39765916

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/055052 WO2008114812A1 (en) 2007-03-19 2008-03-19 Jak inhibitor

Country Status (1)

Country Link
WO (1) WO2008114812A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
CN103804299A (en) * 2012-11-14 2014-05-21 韩冰 Compound with neuroprotective effect and use thereof
CN103804305A (en) * 2012-11-05 2014-05-21 韩文毅 Compound for treating eczema and application thereof
CN103804362A (en) * 2012-11-12 2014-05-21 韩文毅 Compounds for treating diabetes and application thereof
CN103800337A (en) * 2012-11-07 2014-05-21 韩冰 Compound for treating neurodegenerative diseases and application thereof
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
JP2018153194A (en) * 2011-04-28 2018-10-04 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ Hsp90 combination therapy
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020212395A1 (en) 2019-04-16 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0532059A (en) * 1991-07-26 1993-02-09 Konica Corp Image forming method and apparatus
WO2005012257A1 (en) * 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. Indazole derivatives
WO2005012258A1 (en) * 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. Protein kinase inhibitor
WO2006080450A1 (en) * 2005-01-27 2006-08-03 Kyowa Hakko Kogyo Co., Ltd. Igf-1r inhibitor
JP2006523721A (en) * 2003-04-16 2006-10-19 シグナル ファーマシューティカルズ，エルエルシー Indazole derivatives as JNK inhibitors
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
WO2008001885A1 (en) * 2006-06-30 2008-01-03 Kyowa Hakko Kirin Co., Ltd. Abl KINASE INHIBITOR
WO2008001886A1 (en) * 2006-06-30 2008-01-03 Kyowa Hakko Kirin Co., Ltd. Aurora inhibitor
WO2008020606A1 (en) * 2006-08-16 2008-02-21 Kyowa Hakko Kirin Co., Ltd. Antiangiogenic agent

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0532059A (en) * 1991-07-26 1993-02-09 Konica Corp Image forming method and apparatus
JP2006523721A (en) * 2003-04-16 2006-10-19 シグナル ファーマシューティカルズ，エルエルシー Indazole derivatives as JNK inhibitors
WO2005012257A1 (en) * 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. Indazole derivatives
WO2005012258A1 (en) * 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. Protein kinase inhibitor
WO2006080450A1 (en) * 2005-01-27 2006-08-03 Kyowa Hakko Kogyo Co., Ltd. Igf-1r inhibitor
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
WO2008001885A1 (en) * 2006-06-30 2008-01-03 Kyowa Hakko Kirin Co., Ltd. Abl KINASE INHIBITOR
WO2008001886A1 (en) * 2006-06-30 2008-01-03 Kyowa Hakko Kirin Co., Ltd. Aurora inhibitor
WO2008020606A1 (en) * 2006-08-16 2008-02-21 Kyowa Hakko Kirin Co., Ltd. Antiangiogenic agent

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018153194A (en) * 2011-04-28 2018-10-04 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ Hsp90 combination therapy
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
CN103804305A (en) * 2012-11-05 2014-05-21 韩文毅 Compound for treating eczema and application thereof
CN103800337A (en) * 2012-11-07 2014-05-21 韩冰 Compound for treating neurodegenerative diseases and application thereof
CN103804362A (en) * 2012-11-12 2014-05-21 韩文毅 Compounds for treating diabetes and application thereof
CN103804299A (en) * 2012-11-14 2014-05-21 韩冰 Compound with neuroprotective effect and use thereof
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020212395A1 (en) 2019-04-16 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Similar Documents

Publication Publication Date Title
WO2008114812A1 (en) Jak inhibitor
WO2008111441A1 (en) Pharmaceutical composition
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
WO2009038064A1 (en) Heterocyclic derivative having inhibitory activity on type-i 11β-hydroxysteroid dehydrogenase
EP1982982A4 (en) Novel coumarin derivative having antitumor activity
MX2011012627A (en) Substituted aminobutyric derivatives as neprilysin inhibitors.
TNSN08407A1 (en) Organic compounds
EP1921077A4 (en) Agent for treating and/or preventing sleep disorder
WO2008126901A1 (en) Nitrogen-containing heterocyclic compound and pharmaceutical composition containing the same
WO2010014930A3 (en) Piperidine derivatives as jak3 inhibitors
WO2009069736A1 (en) Nitrogenated compound
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
PL1753723T3 (en) Substituted quinoline derivatives as mitotic kinesin inhibitors
HK1138262A1 (en) Novel phosphodiesterase inhibitors
WO2009020137A1 (en) Aminopyrazole amide derivative
TN2012000092A1 (en) Therapeutic agent for mood disorders
IN2012DN00770A (en)
WO2006110173A3 (en) Novel compounds
WO2008114505A1 (en) Eg5 inhibitor and agent for treatment of cell proliferative disease containing the same
WO2008156102A1 (en) Pyrazolone derivative and pde inhibitor containing the same as active ingredient
WO2008049997A8 (en) Indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2009057733A1 (en) Novel indole derivative having anti-angiogenic activity
EP1908755A4 (en) Therapeutic agent for restenosis
MX2012002529A (en) Therapeutic agent for anxiety disorders.
WO2008136377A1 (en) Bicyclic heterocyclic compound

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08722442

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08722442

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP